key: cord-0301661-tvwlmeo6
authors: Ryu, Dong-Kyun; Woo, Hye-Min; Kang, Bobin; Noh, Hanmi; Kim, Jong-In; Seo, Ji-Min; Kim, Cheolmin; Kim, Minsoo; Kim, Jun-Won; Kim, Nayoung; Jeon, Pyeonghwa; Lee, Hansaem; Yang, Jeong-Sun; Kim, Kyung-Chang; Lee, Joo-Yeon; Lee, Min-Ho; Oh, Sang-Seok; Chung, Hyo-Young; Kwon, Ki-Sung; Lee, Soo-Young
title: The in vitro and in vivo potency of CT-P59 against Delta and its associated variants of SARS-CoV-2
date: 2021-07-23
journal: bioRxiv
DOI: 10.1101/2021.07.23.453472
sha: ab8dbe25ee635fcbf5587a35193948afdd64bd51
doc_id: 301661
cord_uid: tvwlmeo6

The Delta variant originally from India is rapidly spreading across the world and causes to resurge infections of SARS-CoV-2. We previously reported that CT-P59 presented its in vivo potency against Beta and Gamma variants, despite its reduced activity in cell experiments. Yet, it remains uncertain to exert the antiviral effect of CT-P59 on the Delta and its associated variants (L452R). To tackle this question, we carried out cell tests and animal study. CT-P59 showed reduced antiviral activity but enabled neutralization against Delta, Epsilon, and Kappa variants in cells. In line with in vitro results, the mouse challenge experiment with the Delta variant substantiated in vivo potency of CT-P59 showing symptom remission and virus abrogation in the respiratory tract. Collectively, cell and animal studies showed that CT-P59 is effective against the Delta variant infection, hinting that CT-P59 has therapeutic potency for patients infected with Delta and its associated variants. Highlights CT-P59 exerts the antiviral effect on authentic Delta, Epsilon and Kappa variants in cell-based experiments. CT-P59 showed neutralizing potency against variants including Delta, Epsilon, Kappa, L452R, T478K and P681H pseudovirus variants. The administration of clinically relevant dose of CT-P59 showed in vivo protection against Delta variants in animal challenge experiment.

as Variants of Concern (VOC), respectively. In particular, highly transmissible Delta variants rapidly spread and become dominant in India and other countries [1, 2] . Also, the global dominant Alpha variants were replaced by Delta variants, even in most vaccinated countries such as the United Kingdom and the United States [3, 4] . [5, 6] . The Delta variant has RBD (Receptor Binding Domain) mutations in the spike protein which may contribute to increased infectivity, pathogenicity and immune evasion, resulting in re-infection or resistance to vaccine-elicited antibody and therapeutic antibodies [7] [8] [9] . One of Delta-associated variants, B.1.427 (L452R) and B.1.429 (S13I/W152C/L452R) also known as the Epsilon have L452R mutation, causing reduction in antibody neutralization [10] [11] [12] . Delta and Kappa variants have a P681R mutation at furin cleavage sites (681PRRAR/S686). Recent studies showed that P681R enhances spike cleavage and fusion for viral entry, suggesting augmented transmissibility and pathogenicity [13, 14] . In addition, Mexican variant, B.1.1.519 (T478K/P681H/T732A) has common mutation sites with Delta variant at T478 and P681, in common with Alpha variant (∆69-70/∆144/N501Y/A570D/ P681H/T716I/S982A/D1118H) [15] . T478K was a previously predominant variant in Mexico and located at the interface of RBD and ACE2 (Angiotensin-Converting Enzyme 2) interaction, thereby potentially impacting viral infection [16] . Thus, it is important to assess the impact of mutations within the spike on COVID-19 therapeutics.

The CT-P59 human monoclonal antibody (Regdanvimab) specifically binds to spike of SARS-CoV-2, blocking interaction with ACE2 for viral entry. We have demonstrated that CT-P59 has high potency against the original SARS-CoV-2 in in vitro and in vivo studies and also showed in vitro and in vivo potency against B.1.351 and P.1 [17] [18] [19] . However, it remains uncertain whether CT-P59 has the therapeutic effect on Delta and its associated variants. To this end, we examined the sensitivity to monoclonal CT-P59 against Delta, Epsilon and Kappa variants by cell assays (plaque reduction neutralization test and pseudovirus assay), and animal test using Delta-infected mice. Pseudoviruses for Delta (L452R/T478K/P681R), Epsilon (S13I/W152C/L452R), Kappa (L452R/E484Q/P681R), L452R, T478K, and P681H were produced as previously described [18] .

Binding affinity of CT-P59 to wild type and mutant SARS-CoV-2 RBDs were evaluated by the Octet QK e system (ForteBio). Mutant RBDs (L452R/T478K, and L452R) were purchased from Sino Biological [17, 19] .

PRNT for authentic SARS-CoV-2 variants were carried out as previously described [19] .

Briefly, pre-incubated mixture of variant and CT-P59 was inoculated to VeroE6 cells. After incubation, the neutralization of CT-P59 against each variant was determined as the halfmaximal inhibitory concentration (IC50) using GraphPad Prism6 software.

Luciferase-based pseudovirus assay was performed as previously described [18] . In brief, 

For intranasal infection, mice (n=8 for virus only group as a placebo group and n=9/group for each CT-P59 treatment group) were humanely euthanized by intraperitoneal (IP) injection with a mix of 30 mg/kg Zoletil® (Virbac) and 10 mg/kg Rompun® (Bayer). Subsequently, mice were intranasally inoculated with 1x10 4 PFU of Delta variant in a 30 µL volume. CT-P59 was administered via a single IP injection at dose levels of 5, 20, 40 and 80 mg/kg (equivalent to human doses of 2.5, 10, 20 and 40 mg/kg, based on exposure to mAb from the PK studies) at 8 h post-inoculation. The negative control (n=5) and virus only group mice were administered with formulation buffer via the same route. The body weight and mortality were monitored daily until 6 dpi (days post-inoculation) and lung tissues were collected at scheduled necropsy at 3 dpi (n=3 for the negative control group, n=4 for the virus only group and n=5 for each treatment group) and 6 dpi (n=2 for the negative control group and n=4 for virus only and each treatment group, respectively) for virus quantitation. Animals with 25% body weight loss were euthanized and excluded from statistical analysis.

For the SARS-CoV-2 titration from the respiratory tract, mice were euthanized on 3 and 6 dpi, and lungs were harvested. The lung tissues were homogenized in 1 mL of DMEM media with bead-based homogenizer (Bertin Technologies). The lung supernatant samples were 10-fold serially diluted in DMEM and inoculated to Vero E6 cells in a 24-well plate. After incubation for 1 h, the inoculum was removed and covered with agar-overlay media including 0.5% (w/v) agarose (Lonza) and 2% FBS in MEM. Following incubation at 37°C for 2 days, the cells were fixed with 4% (v/v) paraformaldehyde solution, and stained with 0.2% crystal violet (Sigma).

The number of plaques per well was counted and analyzed.

To investigate the therapeutic efficacy of CT-P59 against Delta and Epsilon variants, we first evaluated the binding affinity of CT-P59 against mutant RBDs (L452R/T478K or L452R) by using BLI (Bio-Layer interferometry). The equilibrium dissociation constant (KD) of CT-P59

against RBD mutant proteins of Delta or Epsilon variant was reduced by 9 ~ 10-fold compared to that against wild-type RBD (Supplementary Table 1 ). Next, we carried out two types of in vitro assays with live or pseudotyped viruses to assess the susceptibility of Delta and its associated variants to CT-P59. CT-P59 showed reduced susceptibility against Delta, Epsilon and Kappa variants with IC50 of 1,237, 365.6~499.5 and 161.5 ng/mL compared to that against wild type (6.76 ng/mL) in PRNT. Approx. 183-, 54~74-, 24-fold reduced susceptibility against Delta, Epsilon and Kappa variants were observed compared to wild type SARS-CoV-2, respectively ( Table 2 and Supplementary Fig. 1A ). In addition, CT-P59 showed approx. 98-, 31-, 50-fold reduced neutralizing activity against Delta (L452R/T478K/P681R), Epsilon (S13I/W152C/L452R) and Kappa (L452R/E484Q/P681R) pseudotyped virus with an IC50 of 21.52 ng/mL, 6.819 ng/mL and 11.08 ng/ml compared to that of D614G pseudovirus (0.219 ng/mL), respectively ( Table 2 and Supplementary Fig. 1B) . Thus, we found that CT-P59 can neutralize Delta and Epsilon variants despite reduced binding affinity and antiviral ability in in vitro experiments. We also tested whether single mutants (L452R, T478K, and P681H) impact neutralization of CT-P59. CT-P59 was less susceptible to L452R (13.22 ng/mL), but retained its own neutralizing effect against T478K (0.213 ng/mL), and P681H (0.378 ng/mL) ( Table 2 and Supplementary Fig. 1B ).

To evaluate whether CT-P59 has an ability to lower viral burden against Delta variant in in vivo Virus only (placebo) group were severely affected by Delta variant, showing the survival rate of 75% at 5 dpi and 0% at 6 dpi, respectively. In contrast, there was no lethality in all CT-P59 treatment groups (Fig. 1 A) . CT-P59 treatment also ameliorated the weight loss of the mice infected with B. decrease for three mice while a single euthanized mouse excluded from statistical analysis at 5 dpi ( Fig. 1 B) .

To examine viral loads in the lower respiratory tract, we performed plaque assay with viruses from lung tissues. CT-P59 significantly abrogated the virus replication in lungs. In the virus only group, the mean virus titer in lung tissues reached 4.1 log10 PFU/mL at 3 dpi and declined to 2.3 log10 PFU/mL at 6 dpi. In contrast, all CT-P59 treatment showed substantial reduction in viral titers at 3 dpi and 6 dpi. At 3 dpi, infectious viral titers were 3.1 and 3.3 log reduced in 5 and 40 mg/kg groups, respectively, while complete reduction was observed in 20 and 80 mg/kg groups. At 6 dpi, no viral titers were detected in all CT P59 treatment (Fig 1 C and D) .

Here, we tested and confirmed in vitro neutralizing ability of CT-P59 against Delta, Epsilon, and Kappa variants in two different cell-based assays which are generally used to evaluate the antiviral effect of therapeutic agents. In general, it's said that PRNT is a gold standard method to assess antivirals, since it is a cell-based assay with authentic viruses to see all the step in viral life cycle from viral entry to release, and re-infection [20] . Pseudovirus assay is broadly used since it is more convenient and known to correlate with PRNT. The advantages over PRNT are to generate mutants you want, simply detect the antiviral activities by measuring luciferase and GFP reporter, and more accessible than Bio-Safety Level 3 Laboratory. However, it's limited to determine the in vivo antiviral efficacy of therapeutics since IC50 calculated from cell-based assay indicates its antiviral ability and it's not reflect the effectiveness of treatment dosage and in vivo environments.

Authorization for the treatment of COVID-19, demonstrating the effectiveness of 500 mg dosage in clinical trial with 100 ng/mL of IC50 against wild type virus [21] . Also, Sotrovimab retains susceptibility against currently circulating variants such as Alpha, Beta, Gamma, Epsilon, and Kappa, in contrast to Bamlanivimab or Etesevimab [22, 23] . Regdanviamb is very potent antibody having 6 ng/mL of IC50 against wild type virus, which is 16.7-fold stronger than Sotrovimab [19] . Moreover, the clinical dosage of Regdanviamb come to 2,400 mg for 60 kg adult, which is 4.8-fold higher than Sotrovimab. The therapeutic ability of Regdanvimab could come to at least 80-fold (16.7 x 4.8) over that of Sotrovimab.

In accordance with in vitro and in vivo potency against Beta and Gamma variants [17, 18] In addition, the biodistribution of monoclonal antibody to target sites i.e., respiratory tracts for COVID-19 is important to translate the in vitro antiviral activity to the in vivo efficacy in terms of pharmacokinetics of patients [24] . Given that a lung to serum concentration ratio is 15% in development of Casirivimab/Imdevimab, and Sotrovimab for the treatment of COVID-19, lung concentrations during the treatment are predicted with the in vitro EC90 to provide the rationale for clinical dosing recommendations [25] [26] [27] . CT-P59 is predicted to achieve sufficient lung epithelial lining fluid concentrations above the IC90 values against Delta and its associated variants during the treatment period. Hence, this biodistribution of CT-P59 supports that expected sufficient concentration in lung could compensate for reduced activity of CT-P59

against Delta and its associated variants in real world. Importantly, the finding that CT-P59 ameliorated clinical symptoms in Delta-infected mice [28] supports effectiveness of CT-P59 in patients by protection from progress into severe COVID-19. To obtain conclusive correlation between animal and human therapeutic effectiveness, it needs to be investigated in patients infected with the delta variant.

In accord with previous studies with Beta and Gamma variants, this study revealed that CT-P59 retained reduced activity to Delta, Epsilon, and Kappa variants in cells, and showed in vivo substantial protection in Delta variant-infected mice, suggesting that the use of CT-P59 could be a curable option to COVID-19 patients infected with these variants and potential variants including identical mutation sites.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper 

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at

Samiran Panda, NIC team, Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

Variants: distribution of case data

Prevention, Variant Proportions

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals, bioRxiv

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Samiran Panda, Balram Bhargava, SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant, bioRxiv

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion, bioRxiv

The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin, bioRxiv

Functional evaluation of proteolytic activation for the SARS-CoV-2 variant B.1.1.7: role of the P681H mutation, bioRxiv

Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawaii Reveals the Worldwide Emerging P681H Mutation, bioRxiv

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

Therapeutic efficacy of CT-P59 against P.1 variant of SARS-CoV-2

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)?

Fact sheet for health care providers ememgency use authorization (EUA) of casirivimab and imdevimab

Fact sheet for healthcare providers emegency use authorization (EUA) of sotrovimab

Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human

Animal and translational models of SARS-CoV-2 infection and COVID-19

Supplementary figure 1. In vitro susceptibility test of CT-P59 against Delta, Epsilon, and Kappa variants

Serially diluted CT-P59 was premixed with indicated variant pseudoviruses followed by inoculation to ACE2-expressing HEK293T cells

This study was supported by a Korea National Institute of Health fund (2021-NI-007-00, 2020-ER5311-00).